Alterity Therap Limited (ATH) TRADING HALT SUSPENDED

20mins delayed


1 Year Return

System message

16 Sept 2019: Updates have been made to Broker Consensus and Highest Dividends.

Get these alerts in your email: Signup Free Here

Alterity Therap Limited Chart

Share price
Market Cap $25.2 million
Today's Movement
Prev. Close
Day Range -
Historical Stats
52w Range -
4w Avg Volume
4w Avg Turnover

ATH Statistics

17 September

1,338 / 2,298

ASX Size Rank

1yr Return

vs Sector (1yr)


vs ASX 200 (1yr)


$25.2 million

Market Cap

Share Issue

868.8 million

All Ords (%)


Short Sold


Current Fundamentals

17 September


PE Ratio

EPS ($)


Earnings Yield


NTA ($)



Dividend Yield

DPS ($)


Gross Div. Yield


Gross DPS ($)


Company Overview

Alterity Therapeutics Limited (ATH, formerly Prana Biotechnology Limited) is an Australian biotechnology company with a focus on the development of pharmaceutical products designed to treat the underlying causes of degeneration of the brain and the eye as the aging process progresses Potential applications for ATH's MPAC (Metal-Protein Attenuating Compound) technology including Alzheimer's, Parkinson's and Huntington's diseases and brain cancer.

Former Names
Prana Biotechnology Ltd (PBT), 11/04/2019

Alterity Therap Limited Logo

Corporate Details

Head Office: Melbourne
Managing Director: Geoffrey Kempler
GICS Sub-Industry: Biotechnology
Date Listed: 28 Mar 2000
Registry: -
Similar Companies: CSL / SRX / MSB / CUV / VLA

Upcoming Calendar

27 Feb 2020 Report (Interim)
28 Aug 2020 Report (Prelim)
28 Aug 2020 Report (Annual)
31 Aug 2020 Report (Annual)

Dividend History

Ex-Date Amount Franking Type Payable
No dividends paid in the last 5 years

See Upcoming Dividends for all ASX companies.


Date Heading Pages File Size Time

Broker Consensus

The buy, hold and sell recommendations from Australian stockbroking firms are combined to form a "broker consensus". See the Consensus Data posts for more information.

ATH is not covered by a major broker.

Directors & Management

About the Data

Name Title Since Bio
Mr David Sinclair Non-Executive Director Apr 2019
Mr Geoffrey Paul Kempler Executive Director, Chief Executive Officer, Executive Chairman Nov 1997
Mr Brian Derek Meltzer Non-Executive Director Dec 1999
Mr Peter Marks Non-Executive Director Jul 2005
Mr Lawrence Gozlan Non-Executive Director Aug 2011
Mr Tristan Edwards Non-Executive Director Apr 2019
Kathryn Andrews Chief Financial Officer N/A
David Stamler Chief Medical Officer and Senior Vice President Clinical Development N/A
Phillip Hains Company Secretary N/A

Director Transactions

About the Data

ATH directors must report any change in shareholding to the ASX within 5 business days.

See Director Transactions for all ASX companies.

Date Director Type Amount Price Value Notes
16/11/18 Ira Shoulson Issued 1,250,000 $0.044 $55,000 Issue of options.

Shareholder Distribution

About the Data

Holding Size 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over Total Shareholders
No. of Shareholders 515 973 458 851 189 2,986

Top 20 Shareholders

About the Data

Name Shares Capital
HSBC Custody Nominees (Australia) Limited 389,889,040 72.61%
Jagen Pty Ltd 15,567,983 2.90%
Baywick Pty Ltd 14,165,000 2.64%
Merrill Lynch (Australia) Nominees Pty Limited 6,006,707 1.12%
P Morgan Nominees Australia Limited 5,867,548 1.09%
Mr James V Babcock 3,980,263 0.74%
Nrb Developments Pty Ltd 2,970,000 0.55%
Citos Super Pty Ltd 2,656,714 0.49%
Moubray Pty Ltd 2,000,000 0.37%
Robert & Ardis James Foundation/C 1,826,024 0.34%
Neurotransmission Pty Ltd 1,672,433 0.31%
Citicorp Nominees Pty Limited 1,562,830 0.29%
Kempler Super Pty Ltd 1,492,212 0.28%
Mr Johnny Boris Martinovich 1,220,122 0.23%
Carlingwood Pty Ltd 1,213,099 0.23%
Ms Jia Lu 1,149,164 0.21%
Dacoma Holdings Pty Limited 1,125,000 0.21%
Mr Lukasz Pieprzyk 1,056,227 0.20%
One Lucky Oak Pty Ltd 1,040,432 0.19%
Mr Nicholas Joseph Boekel 1,000,000 0.19%
All other shareholders 14.81 %

The Top 20 Shareholders of ATH hold 85.19% of shares on issue.

ATH Share Price History

Date Close Change % Change Open High Low Volume Turnover

ATH Historical Data

Download up to 20 years of share price history.

Year Closing Price (30 June) Last Trade

Offical data as published by ASX. See more Data Downloads.

Company Details

Principal Activity: Commercialise research into Parkinsonian movement disorders, Alzheimer's disease, Huntington disease and other neurodegenerative disorders.

Incorporated: in VIC on 11/11/1997 as Prana Corporation Pty Ltd. Incorporation status changed to "Limited" on 26/11/1999. Name changed to Prana Biotechnology Limited on 05/01/2000.

Level 3, 460 Bourke St
Melbourne VIC 3000

All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.